全文获取类型
收费全文 | 107745篇 |
免费 | 10309篇 |
国内免费 | 4065篇 |
专业分类
耳鼻咽喉 | 1400篇 |
儿科学 | 1427篇 |
妇产科学 | 833篇 |
基础医学 | 4564篇 |
口腔科学 | 1147篇 |
临床医学 | 8913篇 |
内科学 | 9609篇 |
皮肤病学 | 1346篇 |
神经病学 | 4651篇 |
特种医学 | 1773篇 |
外国民族医学 | 9篇 |
外科学 | 8240篇 |
综合类 | 24499篇 |
现状与发展 | 10篇 |
一般理论 | 2篇 |
预防医学 | 7372篇 |
眼科学 | 1178篇 |
药学 | 12549篇 |
165篇 | |
中国医学 | 28610篇 |
肿瘤学 | 3822篇 |
出版年
2024年 | 290篇 |
2023年 | 2105篇 |
2022年 | 3651篇 |
2021年 | 5099篇 |
2020年 | 5159篇 |
2019年 | 3755篇 |
2018年 | 3617篇 |
2017年 | 4078篇 |
2016年 | 4503篇 |
2015年 | 4154篇 |
2014年 | 9622篇 |
2013年 | 8472篇 |
2012年 | 8921篇 |
2011年 | 9170篇 |
2010年 | 7577篇 |
2009年 | 5880篇 |
2008年 | 5086篇 |
2007年 | 5321篇 |
2006年 | 4261篇 |
2005年 | 3555篇 |
2004年 | 2919篇 |
2003年 | 2671篇 |
2002年 | 2093篇 |
2001年 | 1952篇 |
2000年 | 1492篇 |
1999年 | 1125篇 |
1998年 | 785篇 |
1997年 | 705篇 |
1996年 | 573篇 |
1995年 | 501篇 |
1994年 | 436篇 |
1993年 | 295篇 |
1992年 | 274篇 |
1991年 | 255篇 |
1990年 | 209篇 |
1989年 | 162篇 |
1988年 | 148篇 |
1987年 | 129篇 |
1986年 | 99篇 |
1985年 | 188篇 |
1984年 | 145篇 |
1983年 | 114篇 |
1982年 | 109篇 |
1981年 | 69篇 |
1980年 | 107篇 |
1979年 | 59篇 |
1978年 | 48篇 |
1977年 | 30篇 |
1976年 | 26篇 |
1972年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
72.
降尿酸是治疗痛风和高尿酸血症的基本方法,目前降尿酸作用途径主要是通过抑制黄嘌呤氧化酶、腺苷脱氨酶等合成酶的活性,或(且)影响肾脏尿酸转运蛋白(OAT1、OAT3、URAT1、GLUT9)等的表达,进而降低尿酸的水平。由于中药治疗高尿酸血症及痛风的作用机制尚不明确,因此本文通过检索中国知网、维普、万方、pubMed、Embase等数据库,对相关文献进行筛选,总结了具有明确降尿酸作用机制的单味中药,并进行功效归类,有助于对其作用机制进一步研究,为防治痛风和高尿酸血症提供更可靠、更安全的中医治疗依据。 相似文献
73.
74.
《Vaccine》2021,39(14):1933-1942
The genetic and antigenic drift associated with the high pathogenicity avian influenza (HPAI) viruses of Goose/Guangdong (Gs/GD) lineage and the emergence of vaccine-resistant field viruses underscores the need for a broadly protective H5 influenza A vaccine. Here, we tested experimental vector herpesvirus of turkey (vHVT)-H5 vaccines containing either wild-type clade 2.3.4.4A-derived H5 inserts or computationally optimized broadly reactive antigen (COBRA) inserts with challenge by homologous and genetically divergent H5 HPAI Gs/GD lineage viruses in chickens. Direct assessment of protection was confirmed for all the tested constructs, which provided clinical protection against the homologous and heterologous H5 HPAI Gs/GD challenge viruses and significantly decreased oropharyngeal shedding titers compared to the sham vaccine. The cross reactivity was assessed by hemagglutinin inhibition (HI) and focus reduction assay against a panel of phylogenetically and antigenically diverse H5 strains. The COBRA-derived H5 inserts elicited antibody responses against antigenically diverse strains, while the wild-type-derived H5 vaccines elicited protection mostly against close antigenically related clades 2.3.4.4A and 2.3.4.4D viruses. In conclusion, the HVT vector, a widely used replicating vaccine platform in poultry, with H5 insert provides clinical protection and significant reduction of viral shedding against homologous and heterologous challenge. In addition, the COBRA-derived inserts have the potential to be used against antigenically distinct co-circulating viruses and future drift variants. 相似文献
75.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
76.
中国医疗保健国际交流促进会皮肤科分会 《中华皮肤科杂志》2021,54(5):371-375
【摘要】 女阴硬化性苔藓是一种反复发作的慢性炎症性疾病,几乎各年龄阶段均可发生,绝经期、围绝经期和青春期前女性更常见。典型损害为象牙白/瓷白色硬化萎缩斑,晚期可发生外阴、尿道、肛门结构畸变,造成性生活、排尿及排便困难。中国医疗保健国际交流促进会皮肤科分会组织多位专家在借鉴国内外临床研究和诊疗指南的基础上,补充了中国专家的经验和观点,制定女阴硬化性苔藓中国专家共识。 相似文献
77.
《Revista brasileira de otorrinolaringologia (English ed.)》2022,88(5):803-811
ObjectivesTo review the evidence pertaining to the association between cow’s milk protein allergy and recurrent acute otitis media and otitis media with effusion.MethodsThe CENTRAL, Web of Science, EMBASE, MEDLINE, LILACS databases, and gray literature were searched.ResultsFour studies were included, identifying the prevalence rates: 0.2% of delayed speech due to chronic otitis media with effusion in 382 children with cow’s milk protein allergy, 10.7% of cow’s milk protein allergy in 242 children who underwent ENT procedures, 40% of cow’s milk protein allergy in 25 children with recurrent otitis media with effusion and higher tendency to otitis media in children with cow’s milk protein allergy of 186 children (1.5 + 0.6 vs. 0.4 + 0.1; p < 0.1).ConclusionConsidering the characteristics and methodological variations of the identified studies, it is not possible to state that there is reliable evidence of an association between cow’s milk protein allergy and otitis media. 相似文献
78.
79.
丁晨云 《实用中西医结合临床》2022,22(7)
脑梗死是缺血性卒中之一,随着人口老龄化发展趋势,目前已越居我国居民致残和死亡的首要病因。中医药治疗脑梗死有着重要特色和优势,目前在医学领域中仍占着不可动摇的地位,现就针对古代医家及近现代医家对中风病中医病因病机认识,以及中医药治疗方面针对经典方、经验方、中成药、中医外治等方面进行总结综述。 相似文献
80.
功能性消化不良(functional dyspepsia, FD)是一种常见的功能性胃肠病(functional gastrointestinal disorder, FGID),属于中医“痞满”“胃脘痛”范畴,多因“气机升降失常”所致。目前,FD发病机制主要涉及脑肠互动异常、胃容受性受损、内脏敏感性增高、胃动力不足、幽门螺杆菌感染、十二指肠异常、心理精神因素等。随着罗马Ⅳ标准的颁布,十二指肠的作用在FD的发病中日益凸显。十二指肠高敏性、十二指肠黏膜屏障受损及十二指肠黏膜低度炎症等在FD病理生理过程中起着非常重要的作用,十二指肠可能是治疗FD的新靶点。本文综述FD发病中十二指肠的作用及中医药研究,为FD的基础研究及临床治疗提供理论依据。 相似文献